---
schema_version: "secwatch.filing_event.v1"
accession: "0001534969-23-000091"
form_type: "8-K"
ticker: "SERA"
cik: "0001534969"
company_name: "SERA PROGNOSTICS, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:01:34.730962+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sera Q2 revenue $123K, net loss $10.5M; appoints interim CEO and CFO

## Summary
- Revenue $123,000 (Q2 2023) vs $78,000 (Q2 2022), up 58% YoY but still minimal.
- Net loss $10.5M vs $11.5M; operating expenses $11.6M vs $11.8M.
- Cash, equivalents, and securities $92.1M as of June 30, 2023.
- Appointed Zhenya Lindgardt interim President/CEO and Austin Aerts interim CFO; headcount reductions in commercial team.
- Engaged strategy firm to evaluate paths to enhance revenue at reduced cost for PreTRM Test commercialization.

## SEC filing metadata
- accession: 0001534969-23-000091
- form_type: 8-K
- ticker: SERA
- cik: 0001534969
- company_name: SERA PROGNOSTICS, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534969/000153496923000091/0001534969-23-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534969/000153496923000091/sera-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534969-23-000091
- JSON: https://secwatch.observer/filing/0001534969-23-000091.json
- Plain text: https://secwatch.observer/filing/0001534969-23-000091.txt

## Key facts
- Earnings Releases
  SERA PROGNOSTICS, INC. reported the second quarter ended June 30, 2023 results: revenue $123,000, net income $10.5 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $123,000
  - Net income: $10.5 million
  - Result: reported results
  source text: our role as a leader in health diagnostics to improve the lives of women and babies through prenatal care.” Second Quarter 2023 Financial Results Second quarter 2023 revenue of $123,000 compared to $78,000 for the same period of 2022. Total operating expenses were $11.6 million, down from $11.8 million for the second quarter of 2022. Research and development
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534969/000153496923000091/0001534969-23-000091-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.